{"nctId":"NCT00554216","briefTitle":"Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults","startDateStruct":{"date":"2007-11"},"conditions":["Obesity"],"count":1267,"armGroups":[{"label":"VI-0521 Low","type":"EXPERIMENTAL","interventionNames":["Drug: VI-0521"]},{"label":"VI-0521 Top","type":"EXPERIMENTAL","interventionNames":["Drug: VI-0521"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo matched phentermine/topiramate"]}],"interventions":[{"name":"VI-0521","otherNames":[]},{"name":"VI-0521","otherNames":[]},{"name":"Placebo matched phentermine/topiramate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Body mass index (BMI) ≥ 35 kg/m2\n* Informed consent\n* 70 years of age or less\n* Triglyceride level ≤ 200 mg/dL with treatment of 0 or 1 medications\n* Blood pressure of ≤ 140/90 mmHg with treatment of 0-2 medications for hypertension\n* Fasting blood glucose level of ≤ 110 mg/dL\n\nExclusion Criteria:\n\n* Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months\n* Clinically significant renal, hepatic or psychiatric disease\n* Unstable thyroid disease or replacement therapy\n* Nephrolithiasis\n* Obesity of known genetic or endocrine origin\n* Participation in a formal weight loss program or lifestyle intervention\n* History of glaucoma or intraocular pressure\n* Pregnancy or breastfeeding\n* Alcohol abuse\n* Smoking cessation within previous 3 months or plans to quit smoking during study\n* Eating disorders\n* Cholelithiasis within past 6 months\n* Excluded medications\n* Type 2 diabetes\n* Previous bariatric surgery\n* History of bipolar disorder or psychosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Weight Loss From Baseline to Week 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"0.395"},{"groupId":"OG001","value":"5.10","spread":"0.538"},{"groupId":"OG002","value":"10.92","spread":"0.392"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With at Least 5% Weight Loss at Week 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"44.9","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":513},"commonTop":["upper respiratory tract infection","headache","constipation","dry mouth","paresthesia"]}}}